Bayer initiated a phase II clinical trial of an investigational inhibitor of G protein-coupled adduction potassium channel 4 in patients with atrial fibrillation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.